Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

Let us delve into some of the TLR agonists in the clinic and why the careful selection of these drugs is crucial.

The team is exploring whether biomarker testing could also identify patients who benefit more from immune checkpoint inhibitors after radiation.

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Newly discovered oncology drugs called “DNA-encoded tri-specific T-cell engagers,” or “DTriTEs,” engage the immune system ...

An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor ...

IO Biotech's first-in-class vaccine performs double duty, killing cancer cells and enhancing the tumor microenvironment. A ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) ...

Despite the massive successes of immunotherapy, which utilizes the body’s immune system as a tool to fight cancer, therapy ...

Ipilimumab, a cancer immunotherapy, reduced scar formation and promoted tissue regeneration in a mouse model of idiopathic ...

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing ...